Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma

Conditions:   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse Intervention:   Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy Sponsors:   Second Affiliated Hospital of Xi'an Jiaotong University;   Nanjing Legend Biotech Co. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials